Question 1

Which vector platform suits which application?

Accepted Answer

Adeno-associated vectors give durable expression in non-dividing tissue without integrating, within a limited cargo capacity. Lentiviral vectors integrate and carry larger cassettes, suiting engineered cell products made outside the body. Adenoviral vectors drive strong transient expression and provoke robust immune responses, which suits vaccines but limits repeat therapeutic use.

Question 2

How is capsid tropism engineered toward a new tissue?

Accepted Answer

Rational substitution at receptor-contacting surfaces, peptide insertion at permissive loop positions, and selection from diversified libraries all serve. Library approaches recover variants without needing a mechanism, but selected pools must be sequenced and individual candidates rebuilt and retested, since enrichment can reflect production advantage rather than genuine tropism.

Question 3

Why does the empty to full particle ratio matter?

Accepted Answer

Particles lacking a genome contribute capsid antigen without any therapeutic benefit, raising immune burden at a given dose. Analytical ultracentrifugation, ion exchange chromatography profiles, charge detection methods and electron microscopy counting all estimate the ratio. Report the method used, because values differ systematically between techniques.

Question 4

How should titre and potency be reported?

Accepted Answer

Genome copies measured by amplification give a physical count, while a transduction assay on a stated cell line gives infectivity. The ratio between them reflects preparation quality and should accompany both figures. Digital amplification improves consistency, and dosing comparisons must be matched on genome copies rather than volume.

Question 5

What immune responses need measuring?

Accepted Answer

Neutralising antibodies against the capsid determine eligibility and block redosing, so measure titres before and after administration. Cellular responses against capsid and transgene product can eliminate transduced cells weeks later. Innate activation shortly after dosing matters too, particularly at high systemic doses where complement involvement has clinical significance.

Question 6

How is biodistribution assessed convincingly?

Accepted Answer

Quantify vector genomes and transgene expression across a panel of tissues, always including liver as the default sink, and dose the engineered and parental vectors at matched genome copies in the same experiment. Species differences in receptor availability are substantial, so state clearly what the chosen model can and cannot predict.

Question 7

What production choices influence vector quality?

Accepted Answer

Packaging cell line, plasmid ratio, transfection method or producer stability, harvest timing and purification route all shift yield, particle composition and residual host material. Characterise the process alongside the vector, since a capsid comparison confounded by different production conditions cannot support conclusions about the engineering itself.

Biotechnology

Biotechnology

Research Frontiers in Viral Vector Development Biology